Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multinational European Trial for OMS/DES
NCT01868269Phase 3Completed
- Sponsor
- Institut Curie
- Start
- Apr 2013
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 3 trial of dexamethasone, cyclophosphamide, rituximab in Opsoclonus myoclonus syndrome (OMS), sponsored by Institut Curie. Started Apr 2013; status: completed.
02
Drugs
dexamethasonecyclophosphamiderituximab
03
Conditions
Opsoclonus myoclonus syndrome (OMS)
Beyond the preview
Go deeper on NCT01868269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01868269.